GLP1R and fatty liver disease: First, this paper discusses drugs that were originally targeted for Type 2 DM such as glucagon-like peptide 1 receptor agonist, pioglitazone, and sodium-glucose transport 2 inhibitors, which are now being considered for treating fatty liver disease.